• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Tilray® Strengthens Presence in Latin America with Acquisition of Alef Biotechnology

Share:

October 15, 2018

Tilray, Inc., a global leader in cannabis research and production, today announced that it has completed an acquisition of its existing import and distribution partner Alef Biotechnology SpA. The acquisition will allow Tilray to import, produce and distribute Tilray branded medical cannabis products in Chile and to create a hub to distribute Tilray products throughout Latin America.

Tilray purchased all the outstanding equity of Alef for approximately C$5,000,000. The purchase was comprised of approximately C$250,000 in cash paid at closing, and C$4,750,000 in Tilray Class 2 common stock, subject to a standard working capital adjustment and Alef achieving certain business milestones within a twelve-month period after closing.

“Today’s announcement marks another milestone for Tilray as we expand our global footprint and solidify our presence in Latin America by officially welcoming Alef to the Tilray team,” said Brendan Kennedy, President and Chief Executive Officer of Tilray. “The Chilean government has been a pioneer legitimizing and regulating medical cannabis in Latin America, and we are thrilled to be investing in one of the region’s most exciting markets for biopharmaceutical development.”

Tilray previously announced a partnership with Alef in February 2017 to import and distribute Tilray products in Chile and Brazil. Alef is currently licensed by the Chilean government to commercially produce medical cannabis and is developing a state-of-the-art facility to domestically produce and process medical cannabis products. Chilean law permits patients to access medical cannabis products under the supervision of a recommending physician.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

As a part of the acquisition, Tilray will retain current Alef employees Alan Nudman as Chief Executive Officer, and Ariel Nudman, as Chief Sales Officer. Alan and Ariel will oversee the strategic growth of Alef Biotechnology under the global leadership of Tilray.

“The agreement with Tilray is an incredibly exciting moment for Alef and the entire medical cannabis community in Latin America,” says Alan Nudman, Chief Executive Officer of Alef. “In partnership with Tilray, Alef was the first company to offer medical cannabis products through pharmacies anywhere in the Americas and we are looking forward to increasing access for patients throughout Latin America through this acquisition.”

Date: October 15, 2018

Source: BusinessWire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • The Race For AI: Here Are The Tech Giants Rushing To Snap Up Artificial Intelligence StartupsThe Race For AI: Here Are The Tech Giants Rushing To Snap Up Artificial Intelligence Startups
  • Former KKR Vet Jim Momtazee Launches Healthcare Investment Firm, Patient Square CapitalFormer KKR Vet Jim Momtazee Launches Healthcare Investment Firm, Patient Square Capital
  • VectivBio Announces Closing of Comet Therapeutics AcquisitionVectivBio Announces Closing of Comet Therapeutics Acquisition
  • UAE Digital Health Startup Altibbi Scores $44MUAE Digital Health Startup Altibbi Scores $44M
  • USFDA Accepts Glenmark’s Application to Initiate a Human Trial of Molecules for Advanced Solid Tumors and LymphomasUSFDA Accepts Glenmark’s Application to Initiate a Human Trial of Molecules for Advanced Solid Tumors and Lymphomas
  • Novant Health Taps Jvion as 1st Partner for Innovation, AI InstituteNovant Health Taps Jvion as 1st Partner for Innovation, AI Institute
  • Range Biotechnologies Raises $5.2M to Advance Proteomics for Precision HealthRange Biotechnologies Raises $5.2M to Advance Proteomics for Precision Health
  • Israel Innovation Authority Launches Pilot with Mayo Clinic, Hartford Health, OthersIsrael Innovation Authority Launches Pilot with Mayo Clinic, Hartford Health, Others

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications